{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:55Z","timestamp":1792782715739,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["82572207"],"award-info":[{"award-number":["82572207"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province, China","award":["2023Y9023"],"award-info":[{"award-number":["2023Y9023"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2022A1515220020"],"award-info":[{"award-number":["2022A1515220020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04493-x","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:45:07Z","timestamp":1784389507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"75","author":[{"given":"Yuting","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"issue":"1","key":"4493_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-03315-7","volume":"30","author":"Z Cao","year":"2025","unstructured":"Cao Z, Wang H, Li Y, Ye S, Lin J, Li T, Leng J, Jiang Y, Bie M, Li L (2025) The global burden and trends of esophageal cancer caused by smoking among men from 1990 to 2021 and projections to 2040: an analysis of the Global Burden of Disease 2021. Eur J Med Res 30(1):1043. https:\/\/doi.org\/10.1186\/s40001-025-03315-7","journal-title":"Eur J Med Res"},{"key":"4493_CR2","doi-asserted-by":"publisher","unstructured":"Jiao Y, Wang T, Fu L, Gao Y, Cheng Z, Xin L, Xu J, Lin H, Wang W, Zhou M, Qi J, Li Z, Wang L (2025) Trends, patterns, and risk factors of esophageal cancer mortality in China, 2008\u20132021: a national mortality surveillance system data analysis. J Adv Res. S2090\u20131232(25)00314\u20135. https:\/\/doi.org\/10.1016\/j.jare.2025.05.021. Epub ahead of print","DOI":"10.1016\/j.jare.2025.05.021"},{"issue":"1","key":"4493_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s12276-024-01369-x","volume":"57","author":"W Guo","year":"2025","unstructured":"Guo W, Zhou B, Dou L, Guo L, Li Y, Qin J, Wang Z, Huai Q, Xue X, Li Y, Ying J, Xue Q, Gao S, He J (2025) Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases. Exp Mol Med 57(1):59\u201371. https:\/\/doi.org\/10.1038\/s12276-024-01369-x","journal-title":"Exp Mol Med"},{"key":"4493_CR4","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2025.2845","author":"L Wang","year":"2025","unstructured":"Wang L, Xu Z, Sun M, He H, Li Z (2025) Advances in the treatment of unresectable locally advanced esophageal squamous carcinoma (review). Mol Clin Oncol. https:\/\/doi.org\/10.3892\/mco.2025.2845","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"4493_CR5","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41375-025-02573-y","volume":"39","author":"M Jerkeman","year":"2025","unstructured":"Jerkeman M, Mellgren K, Sonnevi K, Lisak M, Lagerl\u00f6f I, Kapas B, Sj\u00f6lund H, Toporski J, Hagberg H, Mielke S, Enblad G (2025) Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden. Leukemia 39(5):1256\u20131259. https:\/\/doi.org\/10.1038\/s41375-025-02573-y","journal-title":"Leukemia"},{"issue":"12","key":"4493_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41563-023-01646-6","volume":"22","author":"N Gong","year":"2023","unstructured":"Gong N, Han X, Xue L, El-Mayta R, Metzloff AE, Billingsley MM, Hamilton AG, Mitchell MJ (2023) In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity. Nat Mater 22(12):1571\u20131580. https:\/\/doi.org\/10.1038\/s41563-023-01646-6","journal-title":"Nat Mater"},{"issue":"12","key":"4493_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04100-0","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, Meng Q, Sun H, Zhang X, Yun J, Li B, Wu S, Li X, Yang H, Zhu H, Aschner M, Relucenti M, Familiari G, Chen R (2021) HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. Cell Death Dis 12(12):1109. https:\/\/doi.org\/10.1038\/s41419-021-04100-0","journal-title":"Cell Death Dis"},{"key":"4493_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00465","volume":"8","author":"F Simonetta","year":"2017","unstructured":"Simonetta F, Alvarez M, Negrin RS (2017) Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation. Front Immunol 8:465. https:\/\/doi.org\/10.3389\/fimmu.2017.00465","journal-title":"Front Immunol"},{"issue":"1","key":"4493_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y (2024) Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther 9(1):302. https:\/\/doi.org\/10.1038\/s41392-024-02005-w","journal-title":"Signal Transduct Target Ther"},{"key":"4493_CR10","doi-asserted-by":"publisher","unstructured":"Lei W, Liu H, Deng W, Chen W, Liang Y, Gao W, Yuan X, Guo S, Li P, Wang J, Tong X, Sun YE, Liang A, Qian W (2025) Safety and feasibility of 4\u20131BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nat Cancer 6(5):786\u2013800. https:\/\/doi.org\/10.1038\/s43018-025-00940-3. Epub 2025 Apr 18. Erratum in: Nat Cancer. 2025 Jul;6(7):1295. 10.1038\/s43018\u2013025\u201301026-w","DOI":"10.1038\/s43018-025-00940-3"},{"issue":"6","key":"4493_CR11","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s12015-021-10246-3","volume":"17","author":"R Elahi","year":"2021","unstructured":"Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A (2021) Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects. Stem Cell Rev Rep 17(6):2081\u20132106. https:\/\/doi.org\/10.1007\/s12015-021-10246-3","journal-title":"Stem Cell Rev Rep"},{"issue":"10","key":"4493_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S (2024) CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 21(10):1089\u20131108. https:\/\/doi.org\/10.1038\/s41423-024-01207-0","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"4493_CR13","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.3390\/ijms22126567","volume":"22","author":"W Chen","year":"2021","unstructured":"Chen W, Zhang Z, Zhang S, Zhu P, Ko JK, Yung KK (2021) MUC1: structure, function, and clinic application in epithelial cancers. Int J Mol Sci 22(12):6567. https:\/\/doi.org\/10.3390\/ijms22126567","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4493_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41698-025-01016-2","volume":"9","author":"US Grewal","year":"2025","unstructured":"Grewal US, Kurzrock R (2025) Mucin-1: a promising pan-cancer therapeutic target. NPJ Precis Oncol 9(1):218. https:\/\/doi.org\/10.1038\/s41698-025-01016-2","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"4493_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4161\/cam.23131","volume":"7","author":"TM Horm","year":"2013","unstructured":"Horm TM, Schroeder JA (2013) MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr 7(2):187\u2013198. https:\/\/doi.org\/10.4161\/cam.23131","journal-title":"Cell Adh Migr"},{"issue":"1","key":"4493_CR16","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","volume":"11","author":"K Supimon","year":"2021","unstructured":"Supimon K, Sangsuwannukul T, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, Wongkham S, Junking M, Yenchitsomanus PT (2021) Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Sci Rep 11(1):6276. https:\/\/doi.org\/10.1038\/s41598-021-85747-9","journal-title":"Sci Rep"},{"key":"4493_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1337557","volume":"15","author":"X Lin","year":"2024","unstructured":"Lin X, Guan T, Li Y et al (2024) Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma. Front Immunol 15:1337557. https:\/\/doi.org\/10.3389\/fimmu.2024.1337557","journal-title":"Front Immunol"},{"key":"4493_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1337489","volume":"15","author":"X Lin","year":"2024","unstructured":"Lin X, Guan T, Xu Y et al (2024) Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma. Front Immunol 15:1337489. https:\/\/doi.org\/10.3389\/fimmu.2024.1337489","journal-title":"Front Immunol"},{"issue":"6378","key":"4493_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A et al (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359(6378):920\u2013926. https:\/\/doi.org\/10.1126\/science.aao2774","journal-title":"Science"},{"issue":"2","key":"4493_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100911","volume":"4","author":"HM Wang","year":"2023","unstructured":"Wang HM, Zhang CY, Peng KC et al (2023) Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study. Cell Rep Med 4(2):100911. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100911","journal-title":"Cell Rep Med"},{"issue":"6","key":"4493_CR21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41551-024-01273-9","volume":"9","author":"A Papargyriou","year":"2025","unstructured":"Papargyriou A, Najajreh M, Cook DP et al (2025) Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Nat Biomed Eng 9(6):836\u2013864. https:\/\/doi.org\/10.1038\/s41551-024-01273-9","journal-title":"Nat Biomed Eng"},{"issue":"7","key":"4493_CR22","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel L, Perr\u00e9ard M, Florent R, Divoux J, Coffy S, Vincent A, Gaggioli C, Guasch G, Gidrol X, Weiswald LB, Poulain L (2024) Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med 56(7):1531\u20131551. https:\/\/doi.org\/10.1038\/s12276-024-01272-5","journal-title":"Exp Mol Med"},{"key":"4493_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1652329","volume":"15","author":"J Guo","year":"2025","unstructured":"Guo J, Zhou C, Zhao H, Li H (2025) Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors. Front Oncol 15:1652329. https:\/\/doi.org\/10.3389\/fonc.2025.1652329","journal-title":"Front Oncol"},{"issue":"10","key":"4493_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biom15101407","volume":"15","author":"S Smirnov","year":"2025","unstructured":"Smirnov S, Zaritsky Y, Silonov S, Gavrilova A, Fonin A (2025) Advancing CAR-T therapy for solid tumors: from barriers to clinical progress. Biomolecules 15(10):1407. https:\/\/doi.org\/10.3390\/biom15101407","journal-title":"Biomolecules"},{"issue":"13","key":"4493_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136290","volume":"26","author":"CA Doeppner","year":"2025","unstructured":"Doeppner CA, Binder AK, Bremm F, Feuchter N, D\u00f6rrie J, Schaft N (2025) Rendering NK cells antigen-specific for the therapy of solid tumours. Int J Mol Sci 26(13):6290. https:\/\/doi.org\/10.3390\/ijms26136290","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4493_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04106-z","volume":"74","author":"S Li","year":"2025","unstructured":"Li S, Jing J, Chen Y, Chi E, Wang B, Xie Z, Yang W, Shen H, Pan J (2025) Precision sniper for solid tumors: CAR-NK cell therapy. Cancer Immunol Immunother 74(9):275. https:\/\/doi.org\/10.1007\/s00262-025-04106-z","journal-title":"Cancer Immunol Immunother"},{"key":"4493_CR27","doi-asserted-by":"publisher","unstructured":"Maddineni S, Silberstein JL, Sunwoo JB (2022) Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. J Immunother Cancer 10(5):e004693. https:\/\/doi.org\/10.1136\/jitc-2022-004693. Erratum in: J Immunother Cancer. 2022 Sep;10(9):e004693corr1. 10.1136\/jitc-2022-004693corr1","DOI":"10.1136\/jitc-2022-004693"},{"issue":"5","key":"4493_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.553","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Shi Q, Wang P, Huang C, Tang S, Zhou M, Hu Q, Wu L, Liang D (2024) iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation. MedComm (2020) 5(5):e553. https:\/\/doi.org\/10.1002\/mco2.553","journal-title":"MedComm (2020)"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04493-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04493-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04493-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:09:39Z","timestamp":1792123779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04493-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4493"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04493-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethical Committee of the Cancer Hospital of Shantou University Medical College and the informed consent was obtained from all participants. The studies were conducted in accordance with the local legislation and institutional requirements.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"249"}}